DUBLIN--(BUSINESS WIRE)--The "Depression - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Depression - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.
This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered
- Introduction
- Depression - Overview
- Depression - Therapeutics Development
- Depression - Therapeutics Assessment
- Depression - Companies Involved in Therapeutics Development
- Depression - Drug Profiles
- Depression - Dormant Projects
- Depression - Discontinued Products
- Depression - Product Development Milestones
- Acadia Pharmaceuticals Inc
- Ache Laboratorios Farmaceuticos SA
- Adamed Sp z oo
- Addex Therapeutics Ltd
- Aequus Pharmaceuticals Inc
- Albany Molecular Research Inc
- BioXcel Therapeutics Inc
- Bristol-Myers Squibb Co
- Calico LLC
- Celgene Corp
- Cellix Bio Pvt Ltd
- Celon Pharma SA
- Cerecor Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Intra-Cellular Therapies Inc
- Jiangsu Nhwa Pharmaceutical Corp Ltd
- Johnson & Johnson
- Karuna Pharmaceuticals Inc
- KemPharm Inc
- Kissei Pharmaceutical Co Ltd
- Lead Discovery Center GmbH
- Luye Pharma Group Ltd
- Medlab Clinical Ltd
- Meta-IQ ApS
- Mitsubishi Tanabe Pharma Corp
- Navitor Pharmaceuticals Inc
- Neuralstem Inc
- Neurocrine Biosciences Inc
- Richter Gedeon Nyrt
- Sage Therapeutics Inc
- Shenox Pharmaceuticals LLC
- SK Biopharmaceuticals Co Ltd
- Zysis Ltd
-
and many more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pdq5dx/depression?w=4
